Equity (Tables)

9 Months Ended

Jun. 30, 2022

Equity [Abstract]

Schedule of Stock-based Compensation Expense - By Award Type

The following table sets forth stock-based compensation expense by award type:

	For the Three Months Ended June 30,				For the Nine Months Ended June 30,
(in thousands)	2022		2021		2022		2021
Employee stock options	$	—	$	1	$	—	$	3
RSUs and RSAs	692		573		1,795		1,505
PSUs and PRSAs	708		403		1,602		989
ESPP	—		85		—		258
Outside director equity awards and fees in common stock	123		114		358		255
Total stock-based compensation expense	$	1,523	$	1,176	$	3,755	$	3,010

Schedule of Stock-based Compensation Expense - By Expense Type

The following table sets forth stock-based compensation expense by expense type:

	For the Three Months Ended June 30,				For the Nine Months Ended June 30,
(in thousands)	2022		2021		2022		2021
Cost of revenue	$	275	$	220	$	604	$	564
Selling, general, and administrative	1,001		752		2,537		1,830
Research and development	247		204		614		616
Total stock-based compensation expense	$	1,523	$	1,176	$	3,755	$	3,010

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net (loss) income per share:

	For the Three Months Ended June 30,				For the Nine Months Ended June 30,
(in thousands, except per share data)	2022		2021		2022		2021
Numerator
Net (loss) income	$	(7,649)	$	13,615	$	(7,460)	$	20,568
Denominator
Weighted average number of shares outstanding - basic	37,425		36,768		37,197		33,069
Effect of dilutive securities
Stock options	—		10		—		5
PSUs, RSUs, and restricted stock	—		2,115		—		1,703
Weighted average number of shares outstanding - diluted	37,425		38,893		37,197		34,777
Earnings per share - basic	$	(0.20)	$	0.37	$	(0.20)	$	0.62
Earnings per share - diluted	$	(0.20)	$	0.35	$	(0.20)	$	0.59
Weighted average antidilutive options, unvested restricted RSUs and RSAs, unvested PSUs and ESPP shares excluded from the computation	3,163		2,138		1,315		1,947

Schedule of Common Stock Reserved for Future Issuances

Common stock reserved for future issuances was as follows:

	As of
	June 30, 2022
Exercise of outstanding stock options	13,884
Unvested RSUs and RSAs	2,587,302
Unvested PSUs and PRSAs (at 200% maximum payout)	3,618,106
Issuance of stock-based awards under the Equity Plans	341,304
Purchases under the officer and director share purchase plan	88,741
Total reserved	6,649,337